Safety and efficacy of isolated limb perfusion in elderly melanoma patients

Annals of Surgical Oncology

Volumn 9, Issue 10, 2002, Pages 968-974

  Noorda, E M ^a   Vrouenraets, B C ^a   Nieweg, O E ^a   Van Geel, A N ^b   Eggermont, A M M ^b   Kroon, B B R ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Aged; Chemotherapy; Drug toxicity; Melanoma; Regional perfusion

Indexed keywords

MELPHALAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; LIMB PERFUSION; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; MELANOMA; MORBIDITY; SURGICAL MORTALITY; TOXICITY; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; HUMANS; LENGTH OF STAY; LINEAR MODELS; MALE; MELANOMA; MELPHALAN; MULTIVARIATE ANALYSIS; NETHERLANDS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036897051     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2002.05.011     Document Type: Article

References (30)

1. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg 1996;83:1319-28.
2. Eggermont AMM, Schraffordt Koops H, Kroon BBR, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol 1996;14:2653-65.
3. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: Results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996;14:479-89.
4. Fraker DL, Alexander HR, Andrich M, et al. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995;1:122.
5. Bartlett DL, Grace M, Alexander HR, Libutti SK, Fraker DL. Isolated limb perfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997;80:2084-90.
6. Sonneveld EJ, Vrouenraets BC, van Geel BN, et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma, Eur J Surg Oncol 1996;22:521-7.
7. Vrouenraets BC, Kroon BBR, Ogilvie AC, et al. Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Ann Surg Oncol 1999;6:405-12.
8. Vrouenraets BC, Eggermont AMM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumor necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol 2001;27:390-5.
9. Thomas DR, Ritchie CS. Preoperative assessment of older adults. J Am Geriatr Soc 1995;43:811-21.
10. Polanczyk CA, Marcantonio E, Goldman L, et al. Impact of age on peri-operative complications and length of stay in patients undergoing noncardiac surgery. Ann Intern Med 2001;134:637-43.
11. Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995;345:745-8.
12. Hobler KE. Colon surgery for cancer in the very elderly. Cost and 3-year survival. Ann Surg 1986;203:129-31.
13. Vrouenraets BC, Klaase JM. Kroon BBR, Van Geel BN, Eggermont AMM, Franklin HR. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg 1995;130: 43-7.
14. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
15. Wieberdink J, Benckhuijsen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10.
16. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979.
17. Zenilman ME. Surgery in the elderly. Curr Probl Surg 1998;35: 99-179.
18. Eggermont AMM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1996;26:335-49.
19. Schraffordt Koops H, Garbe C, Hohenberger P. Is isolated limb perfusion of metastatic malignant melanoma of the extremity worthwhile? Eur J Cancer 1996;32A:1633-40.
20. Ariyan S, Poo WJ. Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery 1998; 123:335-43.
21. Leung JM, Dzankic S. Relative importance of preoperative health status versus intraoperative factors in predicting postoperative adverse outcomes in geriatric surgical patients. J Am Geriatr Soc 2001;49:1080-5.
22. Daley J, Khuri SF, Henderson W, et al. Risk adjustment of the postoperative morbidity rate for the comparative assessment of the quality of surgical care: Results of the National Veterans Affairs Surgical Risk Study. J Am Coll Surg 1997;185:328-40.
23. Schwarz RE, Karpeh MS, Brennan MF. Factors predicting hospitalization after operative treatment for gastric carcinoma in patients older than 70 years. J Am Coll Surg 1997;184:9-15.
24. Stam TC, Swaak AJ, de Vries MR, ten Hagen TL, Eggermont AM. Systemic toxicity and cytokine/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage. Ann Surg Oncol 2000;7:268-75.
25. Klaase JM, Kroon BBR, Van Geel BN, Eggermont AMM, Franklin HR, Hart GA. Patient- and treatment-related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities. Am J Surg 1994;167:618-20.
26. van Geel AN, van Wijk J. Wieberdink J. Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer 1989;63:1092-6.
27. Klaase JM, Kroon BBR, van Slooten GW, Benckhuijsen C. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma. Reg Cancer Treat 1992;4:309-12.
28. Sear JW, Rosewarme F. Anaesthesia for surgeons. In: Morris PJ, Malt RA, eds. Oxford Textbook of Surgery New York: Oxford University Press, 1994:53-82.
29. McAleese P, Odling-Smee W. The effect of complications on length of stay. Ann Surg 1994;220:740-4.
30. Klaase JM, Kroon BBR, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg 1994;178:564-72.